Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Journal of Pediatric Gastroenterology and Nutrition

Volumn 66, Issue 3, 2018, Pages 505-515

  Indolfi, Giuseppe ^a   Hierro, Loreto ^b   Dezsofi, Antal ^c   Jahnel, Jörg ^d   Debray, Dominique ^e   Hadzic, Nedim ^f   Czubowski, Piotr ^g   Gupte, Girish ^h   Mozer Glassberg, Yael ⁱ   Van Der Woerd, Wendy ^j   Smets, Françoise ^k   Verkade, Henkjan J ^l   Fischler, Björn ^l,m  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HOSPITAL INFANTIL LA PAZ   (Spain)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^h BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

ⁱ SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

children; direct acting antiviral; hepatitis C virus; meta analysis; systematic review; treatment

Indexed keywords

ALPHA2B INTERFERON; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; GRATISOVIR; HEPACIVIRIN INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS C; CLINICAL EVALUATION; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EMBASE; EUROPE; HEALTH CARE QUALITY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT CARE; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SEROPREVALENCE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNITED STATES; VERTICAL TRANSMISSION; ADOLESCENT; CHILD; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; INFANT; PRACTICE GUIDELINE; PRESCHOOL CHILD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INFANT;

EID: 85042460820     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001872     Document Type: Article

References (68)

1. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Web site http://www.hcvguidelines.org/ Accessed September 20, 2017.
2. EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-94.
3. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed September 20, 2017.
4. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702-26.
5. Thorne C, Indolfi G, Turkova A, et al. Treating hepatitis C virus in children: time for a new paradigm. J Virus Erad 2015;1:203-5.
6. Indolfi G, Thorne C, El Sayed MH, et al. The challenge of treating children with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017;64:851-4.
7. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. http://www.who.int/hepatitis/publications/global-hepatitisreport2017/ en/. Accessed August 20, 2017.
8. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection.JHepatol 2014;61:S45-57.
9. El-Sayed M, Razavi H. Global estimate of HCV infection in the pediatric and adolescent population. J Hepatol 2015;62:831-2.
10. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014;11:28-35.
11. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013;163:1549.e1-52.e1.
12. Hepatitis CDC. C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011;60: 537-41.
13. Layden JE, Phillips RO, Owusu-Ofori S, et al. High frequency of active HCV infection among seropositive cases in West Africa and evidence for multiple transmission pathways. Clin Infect Dis 2015;60:1033-41.
14. Bortolotti F, Verucchi G, Cammà C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900-7.
15. Network EPHCV. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005;41:45-51.
16. RestiM, JaraP,Hierro L, et al.Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003;70:373-7.
17. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80.
18. Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;46(suppl 5):S165-73.
19. Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014;173:1025-31.
20. Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) 2008;68:117-21.
21. Indolfi G, Guido M, Azzari C, et al. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther 2015;13:1225-35.
22. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology 2008;47:836-43.
23. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003;98:660-3.
24. Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416-23.
25. Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004;103:2460-6.
26. García-Monzón C, Jara P, Fernández-Bermejo M, et al. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology 1998;28:1696-701.
27. Guido M, Bortolotti F, Jara P, et al. Liver steatosis in children with chronic hepatitis C. Am J Gastroenterol 2006;101:2611-5.
28. Harris HE, Mieli-Vergani G, Kelly D, et al. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007;45:335-41.
29. Kage M, Fujisawa T, Shiraki K, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997;26:771-5.
30. Mohan P, Barton BA, Narkewicz MR, et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study. Hepatology 2013;58:1580-6.
31. Vogt M, Lang T, Frösner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-70.
32. Iorio R, Giannattasio A, Sepe A, et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005;41:1431-7.
33. González-Peralta RP, Langham MR, Andres JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009;48:630-5.
34. Malik S, Dekio F, Wen JW. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplant 2014;18:E64-8.
35. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8.
36. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8.
37. Sokal EM, Bourgois A, Stéphenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827-31.
38. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
39. Webster DP, Klenerman P, Dusheiko GM, et al. Hepatitis C. Lancet 2015;385:1124-35.
40. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143.
41. AASLD. AASLD Expresses Concern for Cochrane Review of DAAs. https://www.aasld.org/about-aasld/press-room/aasld-expresses-concern-cochrane-review-daas. Accessed August 20, 2017.
42. European Association for the Study of the Liver. Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. J Hepatol 2017;67:663-4.
43. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
44. Al Ali J, Owayed S, Al-Qabandi W, et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010;9:156-60.
45. El-Karaksy HM, Sharaf SA, Mandour IA, et al. Effect of interleukin-10 gene promoter polymorphisms 1082 G/A and 592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Hum Immunol 2016;77:1248-53.
46. Indolfi G, Nebbia G, Cananzi M, et al. Kinetic of virologic response to pegylated interferon and ribavirin in children with chronic hepatitis C predicts the effect of treatment. Pediatr Infect Dis J 2016;35:1300-3.
47. Megahed A, Salem N, Fathy A, et al. Pegylated interferon alpha/ ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. World J Pediatr 2017;13:346-52.
48. Pawlowska M, Pilarczyk M, Halota W. Virologic response to treatment with pegylated interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Monit 2010;16:Cr616-21.
49. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450.e1-8.e1.
50. Shaker OG,NassarYH, NourZA, et al. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. JPediatr GastroenterolNutr 2013;57:155-60.
51. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8.
52. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis c virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10.
53. Murray KF, Balistreri W, Bansal S, et al. Ledipasvir/sofosbuvir ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection. J Hepatol 2017;66:S101.
54. Leung DH, Yao B, Viani RM, et al. ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir-dasabuvir-ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection. J Hepatol 2017;66:S300.
55. El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in Egyptian adolescents with chronic hepatitis C virus Infection. J Hepatol 2017;66:THU412.
56. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122-6.
57. Haber B, Alonso E, Pedreira A, et al. Long-term follow-up of children treated with peginterferon and ribavirin for hepatitis c virus infection. J Pediatr Gastroenterol Nutr 2017;64:89-94.
58. Kelly DA, Haber B, Gonzalez-Peralta RP, et al. Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treatedwith interferon alfa-2b plus ribavirin. JViral Hepat 2012;19:263-70.
59. Dezsofi A, Baumann U, Dhawan A, et al. Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2015;60:408-20.
60. Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008;23:226-30.
61. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009;48:341-7.
62. Younossi ZM, Stepanova M, Balistreri W, et al. High efficacy and significant improvement of quality of life (qol) in adolescent patients with hepatitis c genotype 1 (GT1) treated with sofosbuvir (SOF) and ledipasvir (LDV). Hepatology 2016;64:A709.
63. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011;60: 537-41.
64. Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013;56:961-7.
65. Narkewicz MR, Rosenthal P, Schwarz KB, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010;51:183-6.
66. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
67. Huysentruyt K, Stephenne X, Varma S, et al. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients. Liver Transpl 2017;23:552-3.
68. Psaros-Einberg A, Fischler B. Successful treatment of paediatric hepatitis C with direct acting antivirals in selected cases. Proceedings of the ESPGHAN 50th Annual Meeting; Prague. 2017.